Cover Image

Population pharmacokinetics and exposure-response analyses of varenicline in adolescent smokers

Abstract Varenicline is an approved smoking cessation aid in adults. Population pharmacokinetics (popPK) and exposure-response (ER) (continuous abstinence rates [CAR] weeks 9‒12 and nausea/vomiting incidence) for varenicline in adolescent smokers were characterized using data from two phase 1 and on...

Full description

Saved in:

Bibliographic Details
Main Authors:	Daryl J. Fediuk (Author), Kevin Sweeney (Author), Vaishali Sahasrabudhe (Author), Thomas McRae (Author), Wonkyung Byon (Author)
Format:	Book
Published:	Wiley, 2021-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pregnancy Outcome after Varenicline Exposure in the First Trimester
by: Yusuf Cem Kaplan, et al.
Published: (2014)

End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor
by: Daryl J. Fediuk, et al.
Published: (2021)

Population pharmacokinetic modeling of oral brepocitinib in healthy volunteers and patients with immuno‐inflammatory diseases
by: Farzaneh Maleki, et al.
Published: (2024)

Population pharmacokinetics and exposure‐response analyses of teduglutide in adult and pediatric patients with short bowel syndrome
by: Jean‐Francois Marier, et al.
Published: (2021)

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis
by: Yang Chen, et al.
Published: (2022)

Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers
by: Kwak SS, et al.
Published: (2018)

Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis
by: Sumit Bhatnagar, et al.
Published: (2024)

Population pharmacokinetic and exposure‐response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma
by: Xiaohua Gong, et al.
Published: (2023)

Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer
by: Jenny‐Hoa Nguyen, et al.
Published: (2022)

Population pharmacokinetic and exposure-response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
by: Ekaterina Gibiansky, et al.
Published: (2021)

Nicotine dependence and neuropsychotic effects of varenicline
by: T. M. Bukatina, et al.
Published: (2018)

Evaluation of the cardiovascular effects of varenicline in rats
by: Selçuk EB, et al.
Published: (2015)

Semi-PBPK Modeling and Simulation to Evaluate the Local and Systemic Pharmacokinetics of OC-01(Varenicline) Nasal Spray
by: Xiaofei Wu, et al.
Published: (2022)

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies
by: Xuemin Jiang, et al.
Published: (2021)

VARENICLINE IN PATIENTS WITH CARDIOVASCULAR DISEASES - FRIEND OR ENEMY?
by: Yu. V. Lukina, et al.
Published: (2015)

VARENICLINE IN PATIENTS WITH CARDIOVASCULAR DISEASES - FRIEND OR ENEMY?
by: Yu. V. Lukina, et al.
Published: (2015)

Smoking cessation: an economic analysis and review of varenicline
by: Michele A Faulkner
Published: (2009)

Varenicline: A review of the literature and place in therapy
by: Whitley HP, et al.
Published: (2007)

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC
by: Neeraj Gupta, et al.
Published: (2022)

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials
by: Elena Muensterman, et al.
Published: (2022)

Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study
by: Rong Deng, et al.
Published: (2024)

Pilot safety evaluation of varenicline for the treatment of methamphetamine dependence
by: Todd Zorick, et al.
Published: (2009)

Population pharmacokinetics and exposure-response analyses of SAF-189s in Chinese patients with ALK+/ROS1+ non-small cell lung cancer
by: Yinhui Liu, et al.
Published: (2024)

Proposing a framework to quantify the potential impact of pharmacokinetic drug-drug interactions caused by a new drug candidate by using real world data about the target patient population
by: Simon Dagenais, et al.
Published: (2024)

Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion
by: Paulo Roberto Xavier Tomaz, et al.
Published: (2022)

Pharmacological Basis of the Clinical Efficacy of Varenicline Used to Facilitate Smoking Cessation
by: S. R. Gilyarevskiy
Published: (2019)

Effect of MDR C3435T polymorphism on Varenicline treatment in quit smoking
by: Nurgul Bozkurt, et al.

Addressing varenicline adherence through repackaging in a dose administration aid
by: Drovandi AD, et al.
Published: (2017)

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder
by: Samira J. Merali, et al.
Published: (2023)

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer
by: Karl Brendel, et al.
Published: (2021)

Physiologically‐Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid
by: Ernesto Callegari, et al.
Published: (2021)

Exposure-response analyses of efzofitimod in patients with pulmonary sarcoidosis
by: Gennyne Walker, et al.
Published: (2023)

Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia
by: Xia Pu, et al.
Published: (2021)

Changes in the Pharmacokinetics and Pharmacodynamics of Sildenafil in Cigarette and Cannabis Smokers
by: Mohammed Murtadha, et al.
Published: (2021)

The influence of flip‐flop in population pharmacokinetic analyses
by: Isabelle H. S. Kuan, et al.
Published: (2023)

Individualized Absorption Models in Population Pharmacokinetic Analyses
by: Mutaz M. Jaber, et al.
Published: (2020)

Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review
by: Nadia Minian, et al.
Published: (2024)

Characteristics of first-time varenicline users - A cross-sectional study in Finnish quitters
by: Hanna E. Tervonen, et al.
Published: (2017)

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
by: Colby S. Shemesh, et al.
Published: (2020)

Is the smokers exposure to environmental tobacco smoke negligible?
by: Valerio Federico, et al.
Published: (2010)